ABSTRACT
Recent advances in glomerular biology have expanded our understanding of glomerular diseases, leading to more precise therapeutic options. Since the discovery of the autoantigen phospholipase A2 receptor in primary membranous nephropathy 10 years ago, the serologic evaluation of glomerular diseases has become more detailed and nuanced for nephrologists. In addition to phospholipase A2 receptor antibodies, circulating autoantibodies now include thrombospondin type 1 domain-containing 7A and most recently, neural epidermal growth factor-like 1 protein for membranous nephropathy. Additionally, discoveries in C3 glomerulopathy and fibrillary glomerulonephritis are poised to improve the diagnostic approach to these disorders by using novel biomarkers to complement traditional histologic patterns on kidney biopsy. Although kidney biopsies are considered the gold standard in profiling glomerular diseases, validated novel glomerular biomarkers contribute substantially to the diagnostic and therapeutic approaches through their ability to improve sensitivity, permit dynamic longitudinal monitoring of disease activity, and capture genetic heterogeneity. We describe the value of specific biomarkers in selected glomerular diseases, with the major focus on their clinical applicability.
Subject(s)
Biological Factors/blood , Glomerulonephritis , Biomarkers/blood , Glomerulonephritis/classification , Glomerulonephritis/diagnosis , Glomerulonephritis/immunology , Glomerulonephritis/metabolism , Humans , Reproducibility of ResultsABSTRACT
Approximately 75% of all breast cancers express the oestrogen and/or progesterone receptors. Endocrine therapy is usually effective in these hormone-receptor-positive tumours, but primary and acquired resistance limits its long-term benefit1,2. Here we show that in mouse models of hormone-receptor-positive breast cancer, periodic fasting or a fasting-mimicking diet3-5 enhances the activity of the endocrine therapeutics tamoxifen and fulvestrant by lowering circulating IGF1, insulin and leptin and by inhibiting AKT-mTOR signalling via upregulation of EGR1 and PTEN. When fulvestrant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), adding periodic cycles of a fasting-mimicking diet promotes long-lasting tumour regression and reverts acquired resistance to drug treatment. Moreover, both fasting and a fasting-mimicking diet prevent tamoxifen-induced endometrial hyperplasia. In patients with hormone-receptor-positive breast cancer receiving oestrogen therapy, cycles of a fasting-mimicking diet cause metabolic changes analogous to those observed in mice, including reduced levels of insulin, leptin and IGF1, with the last two remaining low for extended periods. In mice, these long-lasting effects are associated with long-term anti-cancer activity. These results support further clinical studies of a fasting-mimicking diet as an adjuvant to oestrogen therapy in hormone-receptor-positive breast cancer.
Subject(s)
Breast Neoplasms/diet therapy , Breast Neoplasms/drug therapy , Diet Therapy/methods , Fasting/physiology , Fulvestrant/therapeutic use , Animals , Biological Factors/blood , Breast Neoplasms/pathology , Diet, Healthy/methods , Disease Models, Animal , Disease Progression , Drug Resistance, Neoplasm/drug effects , Early Growth Response Protein 1/metabolism , Female , Fulvestrant/administration & dosage , Humans , Insulin/blood , Insulin-Like Growth Factor I/metabolism , Leptin/blood , MCF-7 Cells , Mice, Inbred NOD , Mice, SCID , PTEN Phosphohydrolase/metabolism , Piperazines/administration & dosage , Piperazines/therapeutic use , Pyridines/administration & dosage , Pyridines/therapeutic use , Receptors, Estrogen , Receptors, Progesterone , Tamoxifen/adverse effects , Tamoxifen/therapeutic use , Xenograft Model Antitumor AssaysABSTRACT
OBJECTIVE: Familial Mediterranean Fever is an autoinflammatory disease characterized by inflammatory attacks in serous tissues often accompanied by endothelial dysfunction. This study aimed to evaluate the effect of endothelium-derived hyperpolarizing factor, which is an indicator of endothelial dysfunction in children with familial Mediterranean fever. METHODS: This study include 57 children with familial Mediterranean fever and 31 children as healthy controls. Blood samples were collected from all participants to measure their endothelium-derived hyperpolarizing factor, complete blood count and C-reactive protein. In addition, inflammatory markers, mutation analyses, and microalbuminuria were examined only in the patient group. RESULTS: The mean age of the patient group was 9.8 ± 4.0 (2.5-18) years, while the mean age of control group was 9.5 ± 3.9 (2.5-16) years (p=0.808). Study group had significantly higher C-reactive protein levels and systolic and diastolic blood pressures and lower endothelium-derived hyperpolarizing factor values than the control group (p=0.0001, p=0.002, p=0.035 and p=0.009, respectively). CONCLUSION: Low levels of endothelium-derived hyperpolarizing factor, high levels C-reactive protein and high blood pressure in patients with familial Mediterranean fever can be attributed to the changes in the endothelium resulting from subacute inflammation.
Subject(s)
Biological Factors/blood , C-Reactive Protein/analysis , Familial Mediterranean Fever/blood , Adolescent , Albuminuria/blood , Case-Control Studies , Child , Child, Preschool , Cross-Sectional Studies , Endothelium, Vascular/metabolism , Female , Humans , Hypertension/diagnosis , Male , Mutation , Prospective Studies , Pyrin/genetics , ROC CurveABSTRACT
Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.
Subject(s)
Biological Factors/blood , Drug Monitoring , Adalimumab/blood , Adalimumab/immunology , Adalimumab/therapeutic use , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Factors/immunology , Biological Factors/therapeutic use , Biosimilar Pharmaceuticals/blood , Biosimilar Pharmaceuticals/therapeutic use , HumansABSTRACT
Objective To investigate the relationship between inflammatory factors, oxidative stress and type 1 deiodinase (DIO-1) concentration in patients with chronic renal failure (CRF) with or without euthyroid sick syndrome (ESS). Methods This study recruited patients with CRF and divided them into two groups: group 1 had low free triiodothyronine (FT3) levels; and group 2 had normal FT3 levels. Group 3 consisted of healthy volunteers. Serum levels of interleukin (IL)-6, IL-1ß, tumour necrosis factor (TNF)-α, 8-isoprostane and DIO-1 were measured using enzyme-linked immunosorbent assays. Multiple regression analysis was used to analyse correlations between parameters. Results Sixty patients were enrolled into each group and the groups were comparable in terms of vital signs, white blood cell count, free thyroxine and thyroid stimulating hormone concentrations. The serum DIO-1 concentration was significantly higher in group 2 than in groups 1 and 3. Multivariate regression analysis revealed that the DIO-1 concentration was inversely correlated with the TNF-α concentration. Conclusions Patients with CRF without ESS showed higher concentrations of DIO-1 than patients with ESS. The DIO-1 concentration was inversely correlated with the TNF-α concentration, which might indicate that the inflammatory response was milder in the patients with CRF without ESS than in those with ESS.
Subject(s)
DNA-Binding Proteins/blood , Euthyroid Sick Syndromes/immunology , Inflammation/immunology , Kidney Failure, Chronic/immunology , Oxidative Stress/immunology , Aged , Biological Factors/blood , Biological Factors/immunology , Cytokines/blood , Cytokines/immunology , DNA-Binding Proteins/immunology , Euthyroid Sick Syndromes/blood , Female , Humans , Inflammation/blood , Kidney Failure, Chronic/blood , Male , Middle Aged , Triiodothyronine/blood , Triiodothyronine/immunologyABSTRACT
Diet may modify metabolomic profiles towards higher or lower cardiovascular disease (CVD) risk. We aimed to identify metabolite profiles associated with high adherence to dietary recommendations - the Alternative Healthy Eating Index (AHEI) - and the extent to which metabolites associated with AHEI also predict incident CVD. Relations between AHEI score and 80 circulating lipids and metabolites, quantified by nuclear magnetic resonance metabolomics, were examined using linear regression models in the Whitehall II study (n = 4824, 55.9 ± 6.1 years, 28.0% women) and were replicated in the Cardiovascular Risk in Young Finns Study (n = 1716, 37.7 ± 5.0 years, 56.3% women). We used Cox models to study associations between metabolites and incident CVD over the 15.8-year follow-up in the Whitehall II study. After adjustment for confounders, higher AHEI score (indicating healthier diet) was associated with higher degree of unsaturation of fatty acids (FA) and higher ratios of polyunsaturated FA, omega-3 and docosahexaenoic acid relative to total FA in both Whitehall II and Young Finns studies. A concordance of associations of metabolites with higher AHEI score and lower CVD risk was observed in Whitehall II. Adherence to healthy diet seems to be associated with specific FA that reduce risk of CVD.
Subject(s)
Biological Factors/blood , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/physiopathology , Diet, Healthy , Metabolome , Adult , Cohort Studies , Female , Humans , Magnetic Resonance Spectroscopy , Male , Metabolomics , Middle Aged , Risk AssessmentABSTRACT
BACKGROUND: Plasmodium vivax is one of the leading causes of malaria worldwide. Infections with this parasite cause diverse clinical manifestations, and recent studies revealed that infections with P. vivax can result in severe and fatal disease. Despite these facts, biological traits of the host response and parasite metabolism during P. vivax malaria are still largely underexplored. Parasitemia is clearly related to progression and severity of malaria caused by P. falciparum, however the effects of parasitemia during infections with P. vivax are not well understood. RESULTS: We conducted an exploratory study using a high-resolution metabolomics platform that uncovered significant associations between parasitemia levels and plasma metabolites from 150 patients with P. vivax malaria. Most plasma metabolites were inversely associated with higher levels of parasitemia. Top predicted metabolites are implicated into pathways of heme and lipid metabolism, which include biliverdin, bilirubin, palmitoylcarnitine, stearoylcarnitine, phosphocholine, glycerophosphocholine, oleic acid and omega-carboxy-trinor-leukotriene B4. CONCLUSIONS: The abundance of several plasma metabolites varies according to the levels of parasitemia in patients with P. vivax malaria. Moreover, our data suggest that the host response and/or parasite survival might be affected by metabolites involved in the degradation of heme and metabolism of several lipids. Importantly, these data highlight metabolic pathways that may serve as targets for the development of new antimalarial compounds.
Subject(s)
Host-Pathogen Interactions , Malaria, Vivax/pathology , Metabolome , Parasitemia/pathology , Adult , Aged , Biological Factors/blood , Female , Heme/metabolism , Humans , Lipid Metabolism , Male , Middle Aged , Plasma/chemistry , Young AdultABSTRACT
Multiple sclerosis is a heterogenous disease. Although several EMA-approved disease-modifying treatments including biopharmaceuticals are available, their efficacy is limited, and a certain percentage of patients are always nonresponsive. Drug efficacy monitoring is an important tool to identify these nonresponsive patients early on. Currently, detection of antidrug antibodies and quantification of biological activity are used as methods of efficacy monitoring for interferon beta and natalizumab therapies. For natalizumab and alemtuzumab treatments, drug level quantification could be an essential component of the overall disease management. Thus, utilization and development of strategies to determine treatment response are vital aspects of multiple sclerosis management given the tremendous clinical and economic promise of this tool.
Subject(s)
Biological Factors/blood , Biological Factors/therapeutic use , Multiple Sclerosis/blood , Multiple Sclerosis/drug therapy , Alemtuzumab/blood , Alemtuzumab/therapeutic use , Animals , Antibodies, Monoclonal, Humanized/blood , Antibodies, Monoclonal, Humanized/therapeutic use , Drug Monitoring/methods , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/therapeutic use , Interferon-beta/blood , Interferon-beta/therapeutic use , Treatment OutcomeABSTRACT
It was recently discovered that bisphenol A (BPA) and phthalates are cardiovascular disruptors. Inflammation is central to the initiation and progression of cardiovascular disease (CVD). This study evaluated whether BPA and different phthalate metabolites are associated with the inflammation marker high-sensitivity C-reactive protein (hs-CRP) in healthy Korean adults. This research is part of an ongoing, population-based study of Korean adults (30-64 years of age) conducted at the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC). The study enrolled 200 healthy volunteers (96 men, 104 women). Plasma hs-CRP was measured as an inflammation marker. BPA and five phthalate metabolites in urine were analyzed by using liquid chromatography/tandem mass spectrometry. BPA and monobenzyl phthalate (MBzP) differed significantly between the low-hs-CRP (<2 mg/L) and high-hs-CRP (≥2 mg/L) groups. BPA and MBzP were related to hs-CRP in an inverted L-shaped manner. High BPA levels (≥75th percentile) had significant odd ratios (ORs) for high hs-CRP even after adjusting for confounding factors related to obesity and insulin resistance, such as visceral fat volume, body mass index (BMI), adiponectin, high-density lipoprotein (HDL) cholesterol, hemoglobin A1c (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR) (OR = 2.85; 95 % CI, 1.16-6.97). However, there was no significant association for MBzP ≥75th percentile. BPA was significantly related to high hs-CRP, even after adjusting for factors related to obesity and insulin resistance. Therefore, BPA could have a direct relationship with systemic inflammation regardless of obesity or insulin resistance.
Subject(s)
Benzhydryl Compounds/blood , C-Reactive Protein/analysis , Environmental Exposure/analysis , Environmental Pollutants/blood , Inflammation/blood , Phenols/blood , Adult , Benzhydryl Compounds/toxicity , Benzhydryl Compounds/urine , Biological Factors/blood , Body Mass Index , Confounding Factors, Epidemiologic , Environmental Pollutants/toxicity , Environmental Pollutants/urine , Female , Healthy Volunteers , Humans , Inflammation/epidemiology , Inflammation/urine , Insulin Resistance , Male , Middle Aged , Obesity/blood , Phenols/toxicity , Phenols/urine , Republic of KoreaABSTRACT
Stent implantation into aortocoronary saphenous vein grafts (SVG) releases particulate debris and soluble vasoactive mediators, for example, serotonin. We now analyzed effects of the soluble mediators released into the coronary arterial blood during stent implantation on vasomotion of isolated rat epicardial coronary artery segments and on coronary flow and left ventricular developed pressure in isolated perfused rat hearts. Coronary blood was retrieved during percutaneous SVG intervention using a distal occlusion/aspiration protection device in nine symptomatic patients with stable angina pectoris and a flow-limiting SVG stenosis. The blood was separated into particulate debris and plasma. Responses to coronary plasma were determined in isolated rat epicardial coronary arteries and in isolated, constant pressure-perfused rat hearts (±nitric oxide synthase [NOS] inhibition and ±serotonin receptor blockade, respectively). Coronary aspirate plasma taken after stent implantation induced a stronger vasoconstriction of rat epicardial coronary arteries (52 ± 8% of maximal potassium chloride induced vasoconstriction [% KClmax = 100%]) than plasma taken before stent implantation (12 ± 8% of KClmax); NOS inhibition augmented this vasoconstrictor response (to 110 ± 15% and 24 ± 9% of KClmax). Coronary aspirate plasma taken after stent implantation reduced in isolated perfused rat hearts only under NOS inhibition coronary flow by 17 ± 3% and left ventricular developed pressure by 25 ± 4%. Blockade of serotonin receptors abrogated these effects. Coronary aspirate plasma taken after stent implantation induces vasoconstriction in isolated rat epicardial coronary arteries and reduces coronary flow and left ventricular developed pressure in isolated perfused rat hearts with pharmacologically induced endothelial dysfunction.
Subject(s)
Coronary Vessels/physiopathology , Heart Ventricles/physiopathology , Saphenous Vein/transplantation , Serotonin/administration & dosage , Vasoconstriction , Animals , Biological Factors/administration & dosage , Biological Factors/blood , Coronary Artery Bypass , Humans , Male , Rats , Rats, Inbred Lew , Serotonin/blood , StentsABSTRACT
BACKGROUND: Plasmodium falciparum infection can lead to several clinical manifestations ranging from asymptomatic infections (AM) and uncomplicated malaria (UM) to potentially fatal severe malaria (SM), including cerebral malaria (CM). Factors implicated in the progression towards severe disease are not fully understood. METHODS: In the present study, an enzyme-linked immunosorbent assay (ELISA) method was used to investigate the plasma content of several biomarkers of the immune response, namely Neopterin, sCD163, suPAR, Pentraxin 3 (PTX3), sCD14, Fractalkine (CX3CL1), sTREM-1 and MIG (CXCL9), in patients with distinct clinical manifestations of malaria. The goal of this study was to determine the relative involvement of these inflammatory mediators in the pathogenesis of malaria and test their relevance as biomarkers of disease severity. RESULTS: ROC curve analysis show that children with AM were characterized by high levels of Fractalkine and sCD163 whereas children with UM were distinguishable by the presence of PTX3 in their plasma. Furthermore, principal component analysis indicated that the combination of Fractalkine, MIG, and Neopterin was the best predictor of AM condition, while suPAR, PTX3 and sTREM-1 combination was the best indicator of UM when compared to AM. The association of Neopterin, suPAR and Fractalkine was strongly predictive of SM or CM compared to UM. CONCLUSIONS: The results indicate that the simultaneous evaluation of these bioactive molecules as quantifiable blood parameters may be helpful to get a better insight into the clinical syndromes in children with malaria.
Subject(s)
Biological Factors/blood , Biomarkers/blood , Malaria/diagnosis , Malaria/pathology , Plasma/chemistry , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Humans , Infant , MaleABSTRACT
Signalling pathways underlying the phenomenon of remote ischaemic preconditioning (RPc) cardioprotection are not completely understood. The existing evidence agrees that intact sensory innervation of the remote tissue/organ is required for the release into the systemic circulation of preconditioning factor(s) capable of protecting a transplanted or isolated heart. However, the source and molecular identities of these factors remain unknown. Since the efficacy of RPc cardioprotection is critically dependent upon vagal activity and muscarinic mechanisms, we hypothesized that the humoral RPc factor is produced by the internal organ(s), which receive rich parasympathetic innervation. In a rat model of myocardial ischaemia/reperfusion injury we determined the efficacy of limb RPc in establishing cardioprotection after denervation of various visceral organs by sectioning celiac, hepatic, anterior and posterior gastric branches of the vagus nerve. Electrical stimulation was applied to individually sectioned branches to determine whether enhanced vagal input to a particular target area is sufficient to establish cardioprotection. It was found that RPc cardioprotection is abolished in conditions of either total subdiaphragmatic vagotomy, gastric vagotomy or sectioning of the posterior gastric branch. The efficacy of RPc cardioprotection was preserved when hepatic, celiac or anterior gastric vagal branches were cut. In the absence of remote ischaemia/reperfusion, electrical stimulation of the posterior gastric branch reduced infarct size, mimicking the effect of RPc. These data suggest that the circulating factor (or factors) of RPc are produced and released into the systemic circulation by the visceral organ(s) innervated by the posterior gastric branch of the vagus nerve.
Subject(s)
Biological Factors/metabolism , Hindlimb/blood supply , Ischemia/blood , Ischemic Preconditioning , Myocardial Reperfusion Injury/prevention & control , Parasympathetic Nervous System/physiology , Vagus Nerve/physiology , Animals , Autonomic Denervation , Biological Factors/blood , Celiac Plexus/physiology , Constriction , Electric Stimulation , Ischemia/physiopathology , Ischemic Preconditioning/methods , Male , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/pathology , Organ Specificity , Rats , Rats, Sprague-Dawley , Stomach/innervation , Vagotomy , Viscera/innervationABSTRACT
SUMMARY: A 39-year-old woman was diagnosed with Systemic lupus erthymatosus (SLE) in 1993, and initially received 30 mg of prednisolone (PSL) daily as treatment. In 2012, the patient was diagnosed with pregnancy-induced hypertension (PIH) complecated with proteinurea, hypertension and pretibial edema at 24 weeks of gestation. At onset, protein urea was 1.6 g/day and she was given bed rest in the hospital with a protein-restricted and low salt diet, which led to a decrease in protein urea to approximately 1 g/day. At 34 weeks of gestation epigastric pain developed, and laboratory examinations showed liver dysfunction and low platelets. We made a diagnosis of hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome and performed an emergency cesarean procedure. Thereafter blood pressure was elevated, protein urea was 3.2 g/daily, anti-ds-DNA antibody level was elevated and serum C3/C4/CH50 was reduced, thus we gave. plasma exchange therapy, along with immunoadsorption and steroid pulse therapy (methyl-prednisolone 500 mg/daily for 3 days), as well as PSL at 30 mg/day. Overtime clinical symptoms and laboratory data gradually improved. CONCLUSION: Some reports suggest that SLE during pregnancy is a risk factor for hypertension, nephritis, SLE relapse and HELLP syndrome. In the patient, ADAMTS13 activity did not decrease, while there was an increase in VW factor level. We assessed this case was as atypical thrombotic microangiopathy. And herein report HELLP syndrome during pregnancy associated with SLE in our patient.
Subject(s)
Antiphospholipid Syndrome/complications , Biological Factors/blood , HELLP Syndrome/diagnosis , HELLP Syndrome/etiology , Lupus Erythematosus, Systemic/complications , Pregnancy Complications , von Willebrand Factor/analysis , ADAM Proteins , ADAMTS13 Protein , Adult , Cesarean Section , Disease Progression , Emergencies , Female , Humans , Pregnancy , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/etiologyABSTRACT
Preeclampsia is a pregnancy-associated disorder characterized by hypertension, and could lead to maternal and fetal morbidity and mortality; however, the pathophysiological mechanisms involved are unclear. Predisposing demographic, genetic and environmental risk factors could cause localized abnormalities in uteroplacental cytoactive factors such as integrins, matrix metalloproteinases, cytokines and major histocompatibility complex molecules leading to decreased vascular remodeling, uteroplacental vasoconstriction, trophoblast cells apoptosis, and abnormal development of the placenta. Defective placentation and decreased trophoblast invasion of the myometrium cause reduction in uteroplacental perfusion pressure (RUPP) and placental ischemia/hypoxia, an important event in preeclampsia. RUPP could stimulate the release of circulating bioactive factors such as the anti-angiogenic factors soluble fms-like tyrosine kinase-1 and soluble endoglin that cause imbalance with the pro-angiogenic factors vascular endothelial growth factor and placental growth factor, or cause the release of inflammatory cytokines, reactive oxygen species, hypoxia-induced factor-1 and AT1 angiotensin receptor agonistic autoantibodies. The circulating bioactive factors target endothelial cells causing generalized endotheliosis, endothelial dysfunction, decreased vasodilators such as nitric oxide and prostacyclin and increased vasoconstrictors such as endothelin-1 and thromboxane A2, leading to increased vasoconstriction. The bioactive factors also stimulate the mechanisms of VSM contraction including Ca(2+), protein kinase C, and Rho-kinase and induce extracellular matrix remodeling leading to further vasoconstriction and hypertension. While therapeutic options are currently limited, understanding the underlying mechanisms could help design new interventions for management of preeclampsia.
Subject(s)
Biological Factors/blood , Blood Circulation , Hypertension, Pregnancy-Induced/metabolism , Ischemia/metabolism , Placenta/blood supply , Angiogenic Proteins/blood , Animals , Cytokines/blood , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Female , Humans , Hypertension, Pregnancy-Induced/genetics , Hypertension, Pregnancy-Induced/physiopathology , Hypoxia/metabolism , Hypoxia/physiopathology , Integrins/blood , Ischemia/physiopathology , Matrix Metalloproteinases/blood , Placental Circulation , Pre-Eclampsia/genetics , Pre-Eclampsia/metabolism , Pre-Eclampsia/physiopathology , Pregnancy , Reactive Oxygen Species/blood , VasodilationABSTRACT
Despite the widespread use of anti-TNF agents for inflammatory bowel disease (IBD), the need for surgical intervention remains high. As a result, many IBD patients undergoing surgery have recently been exposed to biologic agents. There is considerable controversy regarding the potential adverse effects of biologic agents on surgical outcomes in IBD patients undergoing major colorectal surgery with studies showing conflicting results. There appears to be discordance in the systemic bioavailability of anti-TNF-α in patients with Crohn's disease (CD) versus ulcerative colitis, with greater systemic absorption in CD. In patients with CD, preoperative serum anti-TNF-α levels may help guide timing of surgery as patients with elevated serum anti-TNF-α levels appear to be at higher risk for complications. In patients with ulcerative colitis there is likely no need for stopping biologic agents before surgery as there is poor systemic bioavailability of the drug in a majority of patients.
Subject(s)
Biological Factors/administration & dosage , Colitis, Ulcerative/surgery , Crohn Disease/surgery , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Withholding Treatment , Biological Factors/blood , Colitis, Ulcerative/blood , Colitis, Ulcerative/drug therapy , Crohn Disease/blood , Crohn Disease/drug therapy , Humans , Wound Healing/drug effectsABSTRACT
Hepcidin transcription is strongly down-regulated under hypoxic conditions, however whether hypoxia inhibits hepcidin directly or indirectly is still unknown. We investigated the time course of hypoxia-mediated hepcidin down-regulation in vivo in healthy volunteers exposed to hypobaric hypoxia at high altitude and, based on the hypothesis that circulating factors are implicated in hepcidin inhibition, we analyzed the effect of sera of these volunteers exposed to normoxia and hypoxia on hepcidin expression in Huh-7 cell lines. Hypoxia led to a significant hepcidin down-regulation in vivo that was almost complete within 72h of exposure and followed erythropoietin induction. This delay in hepcidin down-regulation suggests the existence of soluble factor/s regulating hepcidin production. We then stimulated HuH-7 cells with normoxic and hypoxic sera to analyze the effects of sera on hepcidin regulation. Hypoxic sera had a significant inhibitory effect on hepcidin promoter activity assessed by a luciferase assay, although the amount of such decrease was not as relevant as that observed in vivo. Cellular mRNA analysis showed that a number of volunteers' sera inhibited hepcidin expression, concurrently with ID1 inhibition, suggesting that inhibitory factor(s) may act through the SMAD-pathway.
Subject(s)
Biological Factors/pharmacology , Hepatocytes/drug effects , Hepcidins/genetics , Hypoxia/blood , RNA, Messenger/genetics , Adult , Altitude , Biological Factors/blood , Cell Line , Erythropoietin/genetics , Erythropoietin/metabolism , Female , Gene Expression Regulation , Genes, Reporter , Hepatocytes/cytology , Hepatocytes/metabolism , Hepcidins/antagonists & inhibitors , Hepcidins/metabolism , Humans , Inhibitor of Differentiation Protein 1/antagonists & inhibitors , Inhibitor of Differentiation Protein 1/genetics , Inhibitor of Differentiation Protein 1/metabolism , Luciferases/genetics , Luciferases/metabolism , Male , Promoter Regions, Genetic , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/metabolism , Signal Transduction , Smad Proteins/genetics , Smad Proteins/metabolismABSTRACT
Metabolic syndrome is associated with both schizophrenia and antipsychotic medication, especially clozapine, with alterations in inflammatory cytokines and adipokines. However, the data in this field is heterogeneous and the sample sizes of the patients are limited. In this study we assessed the serum levels of cytokines/adipokines IL-6, IL-1Ra, hs-CRP and adiponectin, and components of metabolic syndrome in 190 patients with treatment resistant schizophrenia treated with clozapine. Substantial metabolic comorbidity was found in this patient group; overweight/obesity, smoking, hypertriglyceridemia, low HDL-cholesterol, high HOMA-IR, low adiponectin levels, elevated hs-CRP levels and elevated IL-1Ra levels. Elevated IL-1Ra levels are associated with insulin resistance, obesity and hypertriglyceridemia. Low adiponectin levels were associated with hypertriglyceridemia, low HDL cholesterol and high glucose, and in male patients also with obesity and high IL-1Ra levels. After controlling for confounding factors age and smoking, levels of IL-1Ra and hs-CRP associated with obesity, and the levels of IL-6 associated with obesity in female patients. We conclude that there are partly gender dependent cytokine and adipokine alterations in patients with schizophrenia on clozapine treatment associated with metabolic comorbidity. The genetic background of these cytokine alterations needs to be further investigated.
Subject(s)
Adipokines/blood , Clozapine/therapeutic use , Cytokines/blood , Schizophrenia/blood , Schizophrenia/drug therapy , Adiponectin/blood , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Biological Factors/blood , Clozapine/adverse effects , Cytokines/drug effects , Female , Humans , Interleukin 1 Receptor Antagonist Protein/blood , Interleukin-6/blood , Male , Metabolic Syndrome/blood , Metabolic Syndrome/diagnosis , Metabolic Syndrome/etiology , Middle Aged , Schizophrenia/complicationsABSTRACT
OBJECTIVE: To systematically analyze literature with the aim of examining whether rheumatoid factor (RF) is a predictor of response to tumor necrosis factor (TNF) antagonists in rheumatoid arthritis (RA). METHODS: A systematic review and meta-analysis of observational studies were conducted. All studies on the association of baseline RF (titer and/or status) and response to any TNF antagonists, or with enough information to estimate this association were included. Qualitative analysis and meta-analysis using random-effects approach by type of outcome response and RF test was performed. Risk of publication bias was also evaluated. RESULTS: The systematic review included 18 studies of 4163 identified articles, involving 5703 patients with homogeneous baseline characteristics. The most common outcome to assess response was European League Against Rheumatism (EULAR) response criteria, normally merging good and moderate categories as response. The weighted mean difference (WMD) of baseline IgM RF titer in meta-analysis was higher in the non-responders group [-101.58 (95% CI -156.58,-46.59) I2=0.0]. Combined odds ratios (ORs) of positive IgM RF, positive IgA RF, and positive IgG RF to achieve good/moderate response were 1.08 (0.80, 1.47), I2=40.9%; 0.83 (0.39, 1.73), I2=39.8%, and 1.30 (0.48, 3.51), I2=62.9%, respectively. We did not find an association between a positive IgM RF and EULAR good response or remission. CONCLUSIONS: This meta-analysis does not support baseline IgM RF titer as a predictor of response to TNF antagonists in RA. However, this conclusion is hampered by high heterogeneity in the studies included in this meta-analysis.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/immunology , Rheumatoid Factor/blood , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adolescent , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/drug therapy , Biological Factors/blood , Female , Humans , Male , Middle Aged , Observational Studies as Topic , Prognosis , Treatment Outcome , Young AdultABSTRACT
The use of diagnostic testing in the clinical practice of medicine has been a shifting landscape from the time that the first blood test was utilized. This is no different in the field of immunology and in particular rheumatology. As the field of immunology is relatively young, the clinical tests are not well established and therefore guidelines for use are still under debate. In this review, we seek to look at some of the key autoantibodies, as well as other tests that are available to diagnose suspected rheumatologic disease, and examine how to best use these tests in the clinic. In particular, we will focus on the anti-nuclear antibodies, anti-neutrophil cytoplasmic antibodies, complement, cryoglobulins, rheumatoid factor, and anti-citrullinated protein antibodies.